NCT06970301View on ClinicalTrials.gov

A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

May 4, 2026

Study Completion Date

May 4, 2026

Conditions
Healthy Study Participants
Interventions
DRUG

glovadalen

Study participants will receive doses of glovadalen (UCB0022) at pre-specified time points during the Treatment Period of Part A and Part B.

OTHER

Placebo

Study participants will receive matching placebo at pre-specified time points during the Treatment Period of Part A and Part B.

Trial Locations (1)

91206

RECRUITING

Up0135 1001, Glendale

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY